The first decade of this new millennium saw the first of several important breakthroughs in the treatment of allergic rhinitis and urticaria.
A series of clinical practice guidelines were introduced worldwide and, together with this change, the new generations of non-sedating antihistamines soon became the first-line treatment for these conditions.
The guidelines for treating urticaria recommend that the dose of new-generation, non-sedating antihistamines should be higher—up to four times the standard therapeutic dose—in the event of an inadequate response.
This recommendation requires considerable faith in the safety of these modern antihistamines and immediately leads to the response: “Show me the evidence!”
This symposium involves three excellent speakers who have played a key role in the development and implementation of guidelines for allergic rhinitis and urticaria.
